Glenmark Pharmaceuticals introduces Fingolimod Capsules in US


India-based Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Inc., USA has introduced its Fingolimod Capsules, 0.5 mg in the US market.

The product is the generic version of Gilenya Capsules, 0.5 mg, a multiple sclerosis drug from Novartis Pharmaceuticals.

Sanjeev Krishan — Glenmark North America President said: “We are very pleased to bring to market a lower cost alternative to Gilenya Capsules, 0.5 mg. This launch confirms our commitment to provide quality and affordable pharmaceutical products to patients.”

See also  Neustar to acquire authentication and fraud solution firm TRUSTID

As per IQVIA sales data, Gilenya Capsules, 0.5 mg had annual sales of around $1.8 billion in the US for the 12-month period ending September 2022.

Glenmark Pharmaceuticals said that its present portfolio includes 176 products that are approved for distribution in the US and 47 abbreviated new drug applications (ANDAs) are awaiting approval from the US Food and Drug Administration (FDA).

Share This